NK Cell-Based Cancer Immunotherapy


Cambridge Healthtech Institute 第2届
NK细胞为基础的免疫疗法
新癌症免疫疗法开发为目的之NK细胞利用

第15届Discovery on Target其中一环

本会议以NK细胞为基础的癌症免疫疗法为主题,癌症免疫研究及癌症免疫疗法开发相关研究人员、技术提供商主管将齐聚一堂,讨论NK细胞为基础的癌症免疫疗法药新药发现与临床研究的目前现在课题和机会、最新技术、开发方法等,并分享临床前研究及临床研究、并用疗法研究相关最新情报。

Final Agenda


RECOMMENDED ALL ACCESS PACKAGE:

· September 25 Symposium: Immunomodulatory Small Molecules

· September 25 Short Course: Immunology Basics for Chemists

· September 26-27 Conference: NK Cell-Based Cancer Immunotherapy

· September 27-28 Conference: Targeting Tumor Myeloid Cells

· September 27 Short Course: Impact of Convergence of Immunotherapy and Epigenetics on Drug Discovery

· September 28-29 Symposium: Tackling Rare Diseases


Tuesday, September 26

7:00 am Registration Open and Morning Coffee

ADVANCES IN NK CELL-BASED CANCER IMMUNOTHERAPY

8:00 Welcome Remarks

Kip Harry, Senior Conference Director, Cambridge Healthtech Institute

8:05 Chairperson's Opening Remarks

Karl-Johan Malmberg, M.D., Ph.D., Professor, Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital

8:10 KEYNOTE PRESENTATION: Novel Ways to Target and Activate NK Cells to Treat Cancer

Jeffrey S. Miller, M.D., Deputy Director, Masonic Cancer Center; Director, Cancer Experimental Therapeutics Initiative, University of Minnesota

We have discovered a new subset of NK cells termed adaptive with properties of immunologic memory induced by cytomegalovirus, which we think has potent anti-tumor activity. These cells exhibit enhanced anti-tumor activity in vitro and in vivo. We have recently developed a method to expand these cells from CMV seropositive donors and are testing this product in clinical trials. Lastly, NK cells can be made antigen specific to target tumors through IL-15 tri-specific killer engagers (TriKEs) to enhance the activity of NK cells in the clinic.

8:40 Update: aNK and haNK for Cancer Treatment

Hans Klingemann, M.D., Ph.D., Vice President, Research & Development, NantKwest, Inc.

I will provide an update on clinical trial activities with aNK haNK cells expressing the high affinity Fc-Receptor for combination therapy with mAbs taNK cells engineered to express CARs for neo-epitopes. I will also discuss augmenting NK activity with IL-15 super-agonist Altor 803, as well as optimizing NK target activity through CRISPR-based gene manipulation.

9:10 hnCD16-NK Cells: Cornerstone Approach for Off-the-Shelf Cancer Immunotherapy

Bahram (Bob) Valamehr, Ph.D., MBA, Vice President, Cancer Immunotherapy, Fate Therapeutics, Inc.

Through targeted transgene integration, we produced a clonal pluripotent cell master cell line to continuously produce NK cells engineered to uniformly express a novel high affinity, non-cleavable version of CD16 Fc receptor (hnCD16-NK). Preclinical data highlight the therapeutic value of hnCD16-NK cells as an ideal ADCC-mediated "off-the-shelf" NK cell-based immunotherapeutic product with augmented persistence, anti-tumor capacity, manufacturing reliability and preclinical efficacy.

9:40 Grand Opening Coffee Break in the Exhibit Hall with Poster Viewing

THERAPEUTICALLY TARGETING NK CELLS

10:25 Tetravalent Bispecific NK Cell-Engaging Technology for the Activation of Innate and Adaptive Immunity in Cancer

Martin Treder, Ph.D., CSO, R&D, Affimed

Affimed has developed a pipeline of clinical & preclinical stage NK cell engagers; they are CD16A-specific tetravalent, bispecific antibodies, characterized by high-affinity, specific binding to CD16A and superior NK cell retention compared to conventional antibodies. Strongly differentiating them from marketed therapeutic antibodies is the virtual lack of interference by circulating IgGs. Our NK cell platform has been shown to be safe and to act synergistically in combination with checkpoint modulators, activating both innate and adaptive immunity.

10:55 NK Cell Activation, Desensitization and Inhibition: Approaches to Mobilize NK Cells for Cancer Immunotherapy

David H. Raulet, Ph.D., C.H. Li Professor of Immunology and Pathogenesis; Co-Chair, Department of Molecular and Cell Biology, University of California, Berkeley

Mechanisms of NK inhibition and desensitization will be discussed. Approaches to reverse inhibition and desensitization for cancer therapy will be presented. Importantly, NK cells must be activated in order to target tumor cells. Activation of NK cells requires engagement of activating receptors on NK cells and cues from the innate immune system. Immunotherapeutic approaches being developed by Dragonfly Therapeutics to activate NK cells and target them to tumors will be discussed.

11:25 Discovery and Validation of Novel NK Cell Checkpoints

Jai Rautela, Ph.D., CSO & Co-Founder, oNKo-innate

The description of 'a balance of activating and inhibitory signals' is a necessarily vague understanding of how an NK cell makes the decision to kill a target cell. From this, it appeared that a complex immunotherapeutic strategy would likely be required to improve the anti-tumor function of NK cells. By performing a combination of genetic and small molecule screens we have begun to unravel the major druggable pathways the regulate NK cell function. Our recent discovery of a novel cytokine-induced checkpoint ('CIS') has highlighted the efficacy of these approaches, and suggested that there may, in fact, be relatively few unifying pathways that we can target to improve endogenous or adoptive NK cell function.

11:55 Sponsored Presentation (Opportunity Available)

12:25 pm Session Break

12:35 Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own

1:15 Refreshment Break in the Exhibit Hall with Poster Viewing

NK CELL IMMUNO-ONCOLOGY AND CLINICAL STUDIES

1:50 Chairperson's Remarks

Hans Klingemann, M.D., Ph.D., Vice President, Research & Development, NantKwest, Inc.

1:55 Functional Diversification of Human NK Cells - Implications for Cell-Based Cancer Immunotherapy

Karl-Johan Malmberg, M.D., Ph.D., Professor, Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital

In this talk, I will discuss new insights into the underlying mechanisms behind the functional diversification of human NK cells, including the dynamic imprints caused by NK cell responses to cytomegalovirus infection. In terms of clinical translation, we are currently exploring new strategies to selectively expand tumor reactive NK cell subsets for cancer immunotherapy.

2:25 Utilizing Immunostimulatory Cytokines to Unleash Natural Killer Cell Anti-Tumor Responses

Todd A. Fehniger, M.D., Ph.D., Associate Professor, Medicine, Division of Oncology, Washington University School of Medicine

Memory-like NK cells exhibit enhanced functional response to leukemia and other malignancies in vitro and in vivo, and recently have shown promise in a first-in-human early phase clinical study for patients with acute myeloid leukemia. IL-15 receptor super agonist complexes provide in vivo endogenous IL-15 receptor trans-presentation, and may be harnessed to support the expansion and functional capacity of NK cell in cancer patients. Thus, cytokine function-enabled NK cells represent an innovative translational immunotherapy approach for cancer patients.

2:55 Sponsored Presentation (Opportunity Available)

3:25 Refreshment Break in the Exhibit Hall with Poster Viewing and Poster Competition Winner Announced

4:05 Adoptive Immunotherapy with Expanded NK Cells - The Impact of STAT3 Signaling and Crosstalk with Adaptive Immunity

Dean Anthony Lee, M.D., Ph.D., Professor, Pediatrics; Director, Cellular Therapy and Cancer Immunotherapy Program, Nationwide Children's Hospital; James Comprehensive Cancer Center/Solove Research Institute, The Ohio State University

We developed a system for ex vivo NK cell expansion based on genetically modified feeder cells expressing IL-21, which through STAT3 signaling induces robust activation and proliferation of NK cells from normal donors, patients, cord blood, and embryonic/pluripotent stem cells. We established the GMP infrastructure to manufacture clinical-grade NK cells using this approach, and infused expanded NK cells into patients as monotherapy, in single or repeated infusions, or in combination with chemotherapy or stem cell transplantation.

4:35 Immune Responses in the Cancer Patients Who Receive the Random Donor-Derived Expanded NK Cell

Sungyoo Cho, Ph.D., CSO, Green Cross LabCell

Ex vivo-expanded and highly activated NK cells from random unrelated healthy donors injected into patients with malignant lymphoma or advanced recurrent solid tumors with or without lymphodepletion. Different from CAR-T treatment, there is no SAE and cytokine storm in multiple high dose injection. NK cell treatment shows different from T cell therapy in GvHD/GvT aspect. NK cell persistency and efficacy can control by pre-treatment regimen, and the rejection and antibody induction from recipients can also be controlled.

5:05 Interactive Breakout Discussion Groups

Join a breakout discussion group. These are informal, moderated discussions with brainstorming and interactive problem solving, allowing participants from diverse backgrounds to exchange ideas and experiences and develop future collaborations around a focused topic. Details on the topics and moderators are available on the conference website.

6:05 Welcome Reception in the Exhibit Hall (Sponsorship Opportunity Available)

7:10 Close of Day

Wednesday, September 27

7:30 am Registration Open and Morning Coffee

NK CELL-BASED DEVELOPMENT PLATFORMS FOR CANCER IMMUNOTHERAPY

8:00 Chairperson's Remarks

Bahram (Bob) Valamehr, Ph.D., MBA, Vice President, Cancer Immunotherapy, Fate Therapeutics, Inc.

8:05 Novel CARs, Novel NK Sources for Novel NK Products

Rohit Duggal, Ph.D., Senior Director, Cellular Therapy - TNK, Sorrento Therapeutics

I discuss CARs with specific targeting that result in tumor control, CARs targeting novel antigens, attempts at modification of NK cells from different sources, and NK product development.

8:35 oNKord® - Genetic Update - From Proven Safety to Established Efficacy

Jan Spanholtz, Ph.D., CSO, Glycostem

Glycostem Therapeutics is developing allogeneic cellular immunotherapy to treat various types of cancer. Glycostem's patented industrial applicable production platform technology enables the generation of a multitude of products like expanded stem cells, NK cells, dendritic cells and genetically modified versions of those. The universal allogeneic treatment principle, allowed by the unrestricted use of immune cells in various types of cancer, is enabled by unlimited source of cord blood stem cells.

9:05 Sponsored Presentation (Opportunity Available)

9:35 Coffee Break in the Exhibit Hall with Poster Viewing

TECHNOLOGIES ENABLING NK CELL-BASED CANCER IMMUNOTHERAPY

10:20 Expansion of NK Cells

Eun Young Choi, Ph.D., Researcher, Laboratory, IMMUNISBIO

With 60 cc of patient's peripheral blood, more than 5 billion immune cells can be cultured. The cultured immune cell would consist of 60% natural Killer cell (NK cell) and NKT cell and 40% T cell. With autologous and cytotoxic characteristics of NK cell, it can be effectively used in treating cancer without side effects.

10:50 Autologous ex vivo Expanded NK Cells for Solid Tumor Immunotherapy

Ali Ashkar, D.V.M., Ph.D., Professor, Pathology and Molecular Medicine, McMaster Immunology Research Centre, McMaster University

Recent advances in NK cell expansion and activation have generated renewed interest in adoptive NK cell therapy for cancers. We have expanded NK cells from blood of breast, lung and ovarian cancer patients and have investigated their activities against autologous primary tumor cells. In addition, we have established xenograft models with the primary tumors to study the anti-tumor activities of autologous NK cells against primary tumor cells in vivo. Ex vivo expanded NK cells survive and proliferate in vivo in the presence of autologous PBMCs.

11:20 Enjoy Lunch on Your Own

12:20 pm Plenary Keynote Program

(click here for details)

2:00 Refreshment Break in the Exhibit Hall with Poster Viewing

2:45 Close of Conference

* 活动内容有可能不事先告知作更动及调整。

Choose your language
Chinese
Japanese
Korean
English

Catalog

Celebrating 25 Years

Submit A Poster

View All Sponsors

View Media Partners



免费电子邮件通知服务